智康弘义BIOCITY
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
BioCity presents late-breaking clinical trial results with SC0062 for IgA Nephropathy at ASN Kidney Week 2024 as published in the Journal of the American Society of Nephrology 2024-11-05 11:09
BioCity will present the late-breaking clinical trial data of its ETA selective antagonist SC0062 at the American Society of Nephrology (ASN) 2024 with simultaneous publication of the trial data in the Journal of the American Society of Nephrology (JASN) 2024-10-14 15:38
Breakthrough Therapy Designation (BTD) for BioCity's SC0062, a selective endothelin type A (ETA) antagonist, granted by National Medical Products Administration for IgA nephropathy (IgAN) with proteinuria 2024-09-26 15:10
Impressive preliminary objective response rates (ORR) of 36% in NSCLC and 80% in EGFRmut NSCLC: Interim Results of a Phase 1 Study of BC3195, a First-in-Class ADC Targeting CDH3, Presented by BioCity at ESMO 2024 2024-09-23 17:40
BioCity announces its endothelin receptor A selective antagonist SC0062 met the primary endpoint in IgA nephropathy in 2-SUCCEED trial: a randomized, double-blind, placebo-controlled Phase 2 trial 2024-07-08 13:41
BioCity Announces FDA Clearance of the Investigational New Drug Application for its First-In-Class Antibody Drug Conjugate Targeting Glypican 3 2024-04-09 22:10
BioCity Announces Enrollment Completion of the IgA Nephropathy (IgAN) Cohort in the Randomized, Placebo-controlled Phase II Clinical Trial of the ETA Receptor Antagonist SC0062 2024-02-26 22:38
BioCity announces the first patient dosed with its anti-TIM-3 mAb BC3402 in Combination with IMFINZI for the Treatment of Advanced Hepatocellular Carcinoma in a Phase Ib/II Trial 2023-12-21 08:26
Riding the tide, realize the future: The BD paths for Chinese Biotech 2023-11-15 10:42
BioCity Signs Collaboration Agreement with AstraZeneca on BC3402, a monoclonal antibody targeting anti-TIM-3, in Combination with IMFINZI (durvalumab) for the Treatment of Advanced Hepatocellular Carcinoma in China 2023-09-28 09:46
BioCity announces FDA clearance of Investigational New Drug application for its first-in-class CD3/EGFR bispecific antibody 2023-08-07 16:14
BioCity announces the first patient dosed with its first-in-class CDH3-targeting ADC BC3195 in a Phase 1 Trial 2023-07-20 10:41
BioCity Announces Initiation of a Phase 2 Trial for SC0062, a Promising ETA Receptor Antagonist for Chronic Kidney Disease 2023-06-22 08:02
1